← All trials
NCT07224529
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2026
- Primary completion
- Feb 1, 2027
- Completion date
- Feb 1, 2027
- First posted
- Nov 4, 2025
- Last posted
- Nov 4, 2025
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- Harrow HealthCollaborator
- University of Alabama, BirminghamSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.